Philippe Généreux

Oct 28, 2024 | healio.com | Erik Swain |Katie Kalvaitis |Philippe Généreux |Robert O. Bonow

You've successfully added Intervention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Patients with asymptomatic severe aortic stenosis and myocardial fibrosis did not have better clinical outcomes with TAVR vs. surgery.

Oct 28, 2024 | healio.com | Erik Swain |Richard Smith |Celina M. Yong |Philippe Généreux

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: TAVR was superior to clinical surveillance in patients with asymptomatic severe aortic stenosis. Almost all patients in the clinical surveillance group eventually needed TAVR.

Jul 15, 2024 | onlinelibrary.wiley.com | Toshiki Kuno |Giora Weisz |Philippe Généreux |Bimmer E. Claessen

CONFLICTS OF INTEREST STATEMENT Giora Weisz: Advisory board member—Corindus, Filterlex, TriSol; institutional grant support—Abbott, Ancora, Corindus, CSI, Shock wave, Svelte, V-Wave. Philippe Généreux: Speaker's fees—Abbott Vascular, Edwards Lifesciences, Medtronic, Tryton Medical Inc., Cardinal Health, and Cardiovascular Systems Inc., consulting fees—Abbott Vascular, Boston Scientific, Cardiovascular Systems Inc., and Pi-Cardia; institutional research grant—Boston Scientific.